CompletedNot Applicable

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

United States8 participantsStarted 2007-04

Plain-language summary

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: All patients presenting to the Gynecology outpatient service at a participating institution who meet eligibility requirements may be included in this clinical trial. The eligibility requirements are as follows: * Age ≥18. * Ability to give informed consent. * Patients must have biopsy proven recurrent extramammary Paget's disease confirmed at the participating site. Exclusion Criteria: * Patients with known hypersensitivity to imiquimod. * Pregnant and nursing women are not eligible * Patients with underlying adenocarcinoma on biopsy of lesion confirmed at the participating site.

What they're measuring

Percentage of Participants With Clinical and Histologic Remission

Timeframe: 12 weeks post treatment

Trial details

NCT IDNCT00504023

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01

Results submitted2018-04-05

View on ClinicalTrials.gov More Vulvar Cancer trials